Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | G6PD | P11413 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 4/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 2/20 | 0.70 |
| ▸ | GABRD | O14764 | 2/20 | 0.70 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.70 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.70 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.70 |
| ▸ | GABRE | P78334 | 2/20 | 0.70 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfaxalone SCHEMBL644125 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL350372 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614070 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24766358 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614107 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24675016 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614053 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24765814 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614074 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL9809348 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458399-B1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2012-08-08 | — | — | EP | claimed |
| US-7960367-B2 | Pregnane steroids and their use in the treatment of CNS disorders | UMECRINE AB (SE) | 2011-06-14 | — | — | US | claimed |
| EP-2275109-A2 | Pregnane steroids for use in the treatment of CNS disorders | Umecrine AB (SE) | 2011-01-19 | — | — | EP | claimed |
| US-20070219172-A1 | Selective testicular 11beta-HSD inhibitors for the treatment of hypergonadism associated disorders and modulation of fertility | THE MIRIAM HOSPITAL (US) | 2007-09-20 | — | — | US | claimed |
| US-20070093460-A1 | Methods of using selective 11beta-HSD inhibitors to treat gluocorticoid associated states | RHODE ISLAND HOSPITAL, THE | 2007-04-26 | — | — | US | claimed |
| WO-2007025064-A2 | METHODS OF USING SELECTIVE llβ-HSD INHIBITORS TO TREAT GLUOCORTICOID ASSOCIATED STATES | THE MIRIAM HOSPITAL (US) | 2007-03-01 | — | — | WO | claimed |
| US-20050222099-A1 | Pregnane steroids for use in the treatment of cns disorders | UMECRINE AB (SE) | 2005-10-06 | — | — | US | claimed |
| EP-1458399-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003059357-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2003-07-24 | — | — | WO | claimed |
| WO-2026076495-A1 | METHOD OF TREATMENT OR INHIBITION | TRKB Investments Pty Ltd (AU) | 2026-04-16 | — | — | WO | disclosed |
| EP-2275109-B1 | Pregnane steroids for use in the treatment of CNS disorders | UMECRINE AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| EP-1458399-B1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-8119619-B2 | Pregnane steroids and their use in the treatment of CNS disorders | UMECRINE AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-7960367-B2 | Pregnane steroids and their use in the treatment of CNS disorders | UMECRINE AB (SE) | 2011-06-14 | — | — | US | disclosed |
| WO-2003059357-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2003-07-24 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| EP-0656365-B1 | Substituted 2beta-morpholinoandrostane derivatives | AKZO NOBEL NV (NL) | 1997-04-09 | — | — | EP | disclosed |
| US-5593983-A | PREPARATION BY REACTING SUBSTITUTED /THIO/MORPHOLINE OR SALT AND 2,3-EPOXYANDROSTANE OR 2,3-EPOXY-19-NOR-ANDROSTANE; USE TO INDUCE ANESTHESIA | AKZO NOBEL N.V. (NL) | 1997-01-14 | — | — | US | disclosed |
| EP-0656365-A1 | Substituted 2beta-morpholinoandrostane derivatives | Akzo Nobel N.V. (NL) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219172-A1 | Selective testicular 11beta-HSD inhibitors for the treatment of hypergonadism associated disorders and modulation of fertility | HSD11B1, HSD17B11, HSD11B2 | GABRA1 1911/4885GABRB2 1095/4885G6PD 256/4885 |
| US-20070093460-A1 | Methods of using selective 11beta-HSD inhibitors to treat gluocorticoid associated states | HSD11B2, HSD11B1, HSD17B2 | GABRA1 522/4885GABRB2 228/4885G6PD 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.